Tirzepatide was the first dual GLP-1/GIP agonist to demonstrate that adding GIP activity to GLP-1 produces additive metabolic effects in published trials [4]
Independent licensed healthcare providers on the Eden platform can help assess your eligibility for currently available treatment options and guide you every step of the way
You have a provider-monitored plan that includes routine labs and dose escalation, as described in our GLP-1 weight loss plan online
Under this structure, safety oversight depends on clinician review and pharmacy compliance, while MEDVis controls remain limited to access, billing, and coordination
All descriptions are based on published research and publicly available information
Depending on how your body and blood sugar responds, your healthcare provider might increase it further to 1 mg per week, and then for patients who require additional glycaemic control to 2 mg per week